Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949374 | 0.85 | EPHX1 (0.48) | TDP1HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL4951799 | 0.78 | CHRM1 (0.38) | TDP1HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL1405514 | 0.77 | — | — | |
| SCHEMBL5328559 | 0.77 | — | — | |
| SCHEMBL5328465 | 0.75 | HTT (0.40) | TDP1HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL4949366 | 0.75 | — | — | |
| SCHEMBL3151822 | 0.75 | — | — | |
| SCHEMBL723381 | 0.73 | TDP1 (0.46) | TDP1HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL10633032 | 0.73 | TDP1 (0.36) | TDP1HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL8926873 | 0.72 | CPB1 (0.59) | TDP1HDAC1HDAC2CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465471-B2 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007147155-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20050215623-A1 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1531672-A2 | ANTIMICROBIAL COMPOSITIONS | Novus International, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040175434-A1 | Antimicrobial compositions | NOVUS INTERNATIONAL, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004019683-A2 | ANTIMICROBIAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | PNLIP, ELOVL1, ELOVL5 | TDP1 3303/4885HDAC1 603/4885HDAC2 708/4885 |
| US-20050215623-A1 | Palatability of aquaculture feed | TAS2R3, TAS2R1, TAS2R20 | TDP1 4102/4885HDAC1 997/4885HDAC2 1949/4885 |
| US-20040175434-A1 | Antimicrobial compositions | MRPL21, FPR1, ARG1 | TDP1 3273/4885HDAC1 1055/4885HDAC2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.